Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) Insider Acquires 6,551 Shares

August 6, 2026 by InsiderTrades.com

Key Points

Insider Yuri Maricich bought 6,551 CAMP shares at $1.65 each for approximately $10,809, more than doubling his direct ownership to 12,611 shares.
CAMP4 shares opened at $4.01 after a reported 3.6% decline. The company recently missed quarterly EPS expectations, reporting a $0.32 loss per share versus the $0.21 consensus estimate.
Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and an average price target of $8.36, while recent financing provides funding for CMP-002 but could substantially dilute existing shareholders.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) insider Yuri Maricich acquired 6,551 shares of the stock in a transaction on Monday, August 3rd. The shares were purchased at an average price of $1.65 per share, for a total transaction of $10,809.15. Following the transaction, the insider directly owned 12,611 shares in the company, valued at approximately $20,808.15. This trade represents a 108.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

CAMP4 Therapeutics Stock Down 3.6%

Shares of NASDAQ:CAMP opened at $4.01 on Thursday. The company's 50 day moving average price is $4.02 and its two-hundred day moving average price is $4.31. CAMP4 Therapeutics Corporation has a 12-month low of $1.32 and a 12-month high of $7.75. The firm has a market cap of $208.24 million, a PE ratio of -1.70 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. On average, research analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CAMP. China Universal Asset Management Co. Ltd. bought a new position in shares of CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new stake in CAMP4 Therapeutics during the 4th quarter worth $70,000. State Street Corp increased its holdings in CAMP4 Therapeutics by 52.7% in the 4th quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider's stock worth $243,000 after purchasing an additional 13,700 shares in the last quarter. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics in the 4th quarter worth about $86,000. Finally, OMERS ADMINISTRATION Corp bought a new position in CAMP4 Therapeutics in the fourth quarter valued at about $115,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CAMP. Weiss Ratings downgraded CAMP4 Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, May 21st. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a "buy" rating and a $7.00 price objective on the stock. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the company a "buy" rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Finally, Zacks Research downgraded shares of CAMP4 Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.36.

Read Our Latest Research Report on CAMP

Trending Headlines about CAMP4 Therapeutics

Here are the key news stories impacting CAMP4 Therapeutics this week:

Positive Sentiment: Insider buying signals management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively purchased 36,031 shares at $1.65 per share. The purchases increased their respective holdings, although the transactions were relatively small in dollar terms. Insider purchase filings
Positive Sentiment: CAMP4 raised approximately $50.1 million in the second closing of its private placement. The proceeds are intended to fund CMP-002, the company’s lead antisense oligonucleotide candidate, and its early-stage pipeline. The financing included participation from institutional investors such as Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
Positive Sentiment: CMP-002 moved closer to human testing. CAMP4 said it received Australian regulatory and ethics clearance to begin a Phase 1/2 trial for SYNGAP1-related disorder, a rare neurological disease with no approved disease-modifying therapies. Preclinical testing showed increased SYNGAP1 protein expression and improvements in disease-relevant animal models. CAMP4 financing and CMP-002 update
Negative Sentiment: The financing is materially dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at roughly $1.53 per share-equivalent, potentially expanding the share count significantly. The discounted issuance may weigh on the stock even though it provides additional operating runway.
Neutral Sentiment: Clinical execution remains the key catalyst and risk. The Phase 1/2 trial could provide important validation, but CMP-002 remains investigational and preclinical results do not guarantee safety or efficacy in humans.

About CAMP4 Therapeutics

(Get Free Report)

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.